Core Viewpoint - Zevra Therapeutics, Inc. has granted an equity inducement award to its new Chief Financial Officer, Justin Renz, as part of its strategy to attract talent and enhance its leadership team [1][2]. Group 1: Equity Inducement Award - The company granted Mr. Renz an option to purchase 300,000 shares of common stock with a 10-year term and an exercise price of $9.55, which reflects the closing price on March 18, 2026 [2]. - The option will vest over four years, contingent upon Mr. Renz's continued service [2]. Group 2: Company Overview - Zevra Therapeutics is a commercial-stage company focused on therapies for rare diseases, with a late-stage pipeline aimed at delivering life-changing treatments [3]. - The company is committed to expanding access through geographic opportunities and progressing its pipeline towards key milestones, with its lead product targeting Niemann-Pick disease type C (NPC) [3]. - Zevra's strategic plan emphasizes patient centricity, integrity, accountability, innovation, and courage to deliver long-term value [3].

Companies Resolve Lawsuit in DelawareBOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced an agreement under which Commave Therapeutics SA (Commave) will purchase Zevra’s serdexmethylphenidate (SDX) portfolio, including AZSTARYS® and KP1077, for $50 million. "We are pleased to have reached a mutually beneficial agreement with Commave regardin ...

Zevra Therapeutics Conference Call Summary Company Overview - **Company**: Zevra Therapeutics (NasdaqGS: ZVRA) - **Focus**: Commercial-stage organization specializing in rare diseases, particularly Niemann-Pick disease type C (NPC) and vascular Ehlers-Danlos syndrome Key Points MIPLYFFA Performance - **Launch Success**: MIPLYFFA, the only disease-modifying therapy for NPC, launched successfully with a robust commercial performance [5][12] - **Revenue Growth**: Total revenue reached $106.5 million, marking a 30% quarter-over-quarter growth [12] - **Patient Enrollment**: 24 enrollment forms were submitted in Q4, indicating strong demand [12] Patient Demographics and Diagnosis - **Prevalence and Diagnosis**: Approximately 900 patients in the U.S. are estimated to have NPC, with 300-350 diagnosed [10][18] - **New Diagnoses**: Efforts in genetic testing and disease awareness are leading to an increase in newly diagnosed patients [13][18] - **Patient Journey**: The organization is focused on understanding the unique journey of each patient to improve diagnosis rates [20][23] Clinical Profile and Treatment Impact - **Disease Modification**: MIPLYFFA shows the ability to halt disease progression within 12 weeks, with long-term data supporting efficacy over 4-6 years [11][12] - **Safety Profile**: The therapy has an acceptable safety profile, which is crucial for patient acceptance [11] Geographic Expansion - **International Opportunities**: Zevra is exploring geographic expansion beyond the U.S. and Europe, with plans to increase access to MIPLYFFA [6][39] - **European Market**: The company is seeing a pull for the product in Europe, with 92 patients added in Q3, representing about 10% of the diagnosed population [39] Celiprolol Development - **Ongoing Trials**: Celiprolol is currently enrolling patients for vascular Ehlers-Danlos syndrome, with a focus on accelerating clinical development [6][52] - **Market Potential**: The U.S. prevalence for this condition is approximately 7,500 patients, indicating a significant market opportunity [58] Financial Strategy - **Capital Allocation**: The company emphasizes disciplined capital allocation, allowing for independent operation without reliance on capital markets [54][57] - **Investment Focus**: Investments are being made in MIPLYFFA, Celiprolol, and European market expansion [57] Awareness and Education Efforts - **Healthcare Provider Engagement**: Zevra is actively educating healthcare providers about NPC and MIPLYFFA to improve diagnosis and treatment rates [15][30] - **Genetic Testing Initiatives**: Collaborations with organizations like GeneDx are aimed at facilitating earlier diagnosis through genetic testing [15][16] Future Outlook - **Long-term Vision**: The company aims to continue focusing on MIPLYFFA's growth while developing Celiprolol and expanding its market presence [52][57] - **Market Strategy**: A flexible go-to-market strategy is being developed for Europe and other international markets, considering local dynamics and patient needs [40][43] Additional Insights - **Patient Retention**: High persistency rates are observed, with most patients remaining on therapy unless they progress to a point where therapy is no longer needed [26][29] - **Market Share**: Zevra has captured approximately 40%-50% market share in its first full year of MIPLYFFA's launch [24] This summary encapsulates the key insights from the conference call, highlighting Zevra Therapeutics' strategic focus, market performance, and future growth opportunities in the rare disease sector.

Core Insights - Zevra Therapeutics experienced a significant stock price increase of over 21% following its latest earnings release, indicating strong investor interest [1] Financial Performance - The company reported net revenue of slightly over $34 million for Q4 2025, which is a 44% increase compared to the same period in 2024 [2] - Zevra achieved a net profit of $12.2 million ($0.19 per share) under GAAP, a turnaround from a loss of $35.7 million in the previous year [2][4] Product Success - The substantial revenue growth is largely attributed to the success of Miplyffa, a treatment for Niemann-Pick disease, with net sales increasing nearly ninefold to over $87 million during the quarter [5] - Miplyffa's market penetration has expanded significantly, reaching 68% of covered lives [5] International Expansion - Zevra has filed a marketing authorization application for Miplyffa with the European Medicines Agency, indicating potential for growth in international markets [6]

Financial Performance - In Q4 2025, total net revenue was $34.1 million, including $26.4 million from MIPLYFFA sales, $400,000 from OLPRUVA, $5.6 million from global EAP reimbursements, and $1.8 million from royalties under the AZSTARYS license [22][23] - For the full year 2025, net revenue reached $106.5 million, with $87.4 million from MIPLYFFA sales, $800,000 from OLPRUVA, $13 million from global EAP reimbursements, and $5 million from royalties [24] - Operating expenses for Q4 were $23 million, a decrease of $1.5 million year-over-year, while full-year operating expenses were $90.4 million, down $6.6 million from 2024 [22][24] - Net income for Q4 was $12.2 million, compared to a net loss of $35.7 million in Q4 2024, and full-year net income was $83.2 million, compared to a net loss of $105.5 million in 2024 [23][24] Business Line Performance - MIPLYFFA generated $87.4 million in revenue for the full year 2025, with strong commercial performance reflected in 52 prescription enrollment forms received in the first year of commercialization [5][6] - In Q4, 24 new prescription enrollment forms were received, contributing to a total of 161 enrollments since launch [6][14] - The company is expanding access to MIPLYFFA through a global expanded access program, with 113 patients enrolled by the end of 2025 [8] Market Data - The estimated U.S. prevalence of Niemann-Pick disease type C (NPC) is approximately 900 individuals, with 300-350 currently diagnosed [7] - In Europe, NPC prevalence is estimated at around 1,100 individuals, with the current EAP supporting nearly 10% of this population [9] - Diagnosis rates in Europe are higher due to the approval of miglustat, leading to stronger physician awareness and higher patient identification [10] Company Strategy and Industry Competition - The company aims to redefine therapies for rare diseases, focusing on patient-centricity, integrity, accountability, innovation, and courage [5] - MIPLYFFA has exclusivity in the U.S. through 2031 under the Orphan Drug Designation, and the company is pursuing a patent term extension [7] - The company is also advancing celiprolol for the treatment of vascular Ehlers-Danlos syndrome, with ongoing Phase III studies [10][11] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of MIPLYFFA, driven by both previously diagnosed and newly diagnosed patients [15][16] - The company is focused on expanding access and strengthening relationships with key opinion leaders to maximize commercial impact [10] - Management highlighted the importance of ongoing education and awareness campaigns to facilitate early diagnosis and treatment [16][18] Other Important Information - The company moved its headquarters to Boston to enhance collaboration and access to specialized talent [12][13] - The new CFO, Justin Renz, officially started on the call date and will support the company's long-term value creation [4][28] Q&A Session Summary Question: Can you provide details on the split of new diagnoses versus previously identified patients? - Management noted that there has been meaningful growth in newly diagnosed patients, attributed to clinical data strength and disease awareness campaigns [33][34] Question: What is the expected timeline for diagnosis confirmation? - Management indicated that the timeline for diagnosis can vary significantly due to the nature of rare diseases, but efforts are being made to streamline the process [37][40] Question: Can you discuss persistency rates for patients on therapy? - Management stated that it is too early to provide meaningful data on persistency but expressed encouragement from refill rates observed [45][46] Question: How is the initial experience with the Uniphar collaboration? - Management expressed satisfaction with the collaboration, noting that it has facilitated rapid product delivery to patients [47][48] Question: What is the expected growth of EAP revenue? - Management clarified that EAP revenue is based on individual patient shipments and will have variability quarter-over-quarter [54][55] Question: How is the gross to net evolving in the U.S.? - Management noted that gross to net has evolved and is dynamic, making it difficult to provide specific guidance [58] Question: What is the average age of patients on MIPLYFFA? - Management indicated that approximately half of MIPLYFFA patients are adults, reflecting the patient mix seen in the expanded access program [64][66] Question: What are the next steps for the EMA application? - Management confirmed readiness to respond to the EMA's questions and emphasized the robustness of the data package submitted [69]

Financial Data and Key Metrics Changes - In Q4 2025, total net revenue was $34.1 million, including $26.4 million from MIPLYFFA sales, $400,000 from OLPRUVA, and $5.6 million from net reimbursements under the global EAP [22][23] - For the full year 2025, net revenue reached $106.5 million, with $87.4 million from MIPLYFFA sales, compared to a net loss of $105.5 million in 2024 [25] - Operating expenses for Q4 2025 were $23 million, a decrease of $1.5 million year-over-year, while R&D expenses decreased by $5.8 million to $2.6 million [22][24] Business Line Data and Key Metrics Changes - MIPLYFFA generated $87.4 million in revenue for the full year 2025, with a total of 161 enrollments since launch, including 52 in the first full year of commercialization [5][6][15] - The global expanded access program (EAP) had 113 patients enrolled by the end of 2025, with ongoing efforts to expand access beyond the U.S. [8][9] Market Data and Key Metrics Changes - In the U.S., the estimated prevalence of Niemann-Pick disease type C (NPC) is approximately 900 individuals, with 300-350 currently diagnosed [7][10] - In Europe, the estimated prevalence of NPC is around 1,100 individuals, with the current EAP supporting nearly 10% of this population [9] Company Strategy and Development Direction - The company aims to redefine therapies for rare diseases, focusing on patient-centricity and innovation [4] - A strategic move to Boston is intended to enhance collaboration and access to specialized talent within the biotech ecosystem [12] - The company is pursuing a patent term extension for MIPLYFFA, which could provide additional exclusivity [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of MIPLYFFA, driven by strong clinical data and increased awareness among healthcare providers [15][16] - The company is optimistic about the continued identification of newly diagnosed patients and the overall market potential for MIPLYFFA [16][20] Other Important Information - The company has engaged the FDA regarding regulatory options to accelerate the development of celiprolol for vascular Ehlers-Danlos syndrome [12][70] - The company has a strong balance sheet with $238.9 million in cash and equivalents, allowing for independent operation and investment in growth opportunities [90] Q&A Session Summary Question: Can you provide details on the split of new diagnoses versus previously identified patients? - Management noted that there has been meaningful growth in newly diagnosed patients, attributed to clinical data strength and disease awareness campaigns [32][33] Question: What is the expected timeline for diagnosis confirmation? - The average time for test results is estimated to be about three weeks, facilitating quicker clinical decision-making [41] Question: Can you discuss persistency rates for patients on therapy? - Management indicated that it is too early to provide meaningful data on persistency but noted encouraging refill rates [46][47] Question: How is the initial experience with the Uniphar collaboration? - The company is pleased with the collaboration and expects continued growth in patient access through this partnership [48][49] Question: What is the total addressable market for diagnosed NPC patients? - Management believes they have engaged approximately 40%-50% of the diagnosed patients currently enrolled to receive MIPLYFFA [80]

Product Development and Commercialization - Zevra Therapeutics is focused on the commercialization and global expansion of its lead product, MIPLYFFA, for Niemann-Pick disease type C (NPC), with FDA approval received on September 20, 2024[38]. - MIPLYFFA has been granted orphan drug exclusivity through 2031 and is currently under review for a Marketing Authorization Application (MAA) by the European Medicines Agency (EMA)[42]. - The company completed the acquisition of Acer Therapeutics on November 17, 2023, which included OLPRUVA for urea cycle disorders (UCDs) and a pipeline of investigational product candidates[39]. - For the year ended December 31, 2025, Zevra reported $0.8 million in revenue from sales of OLPRUVA, while evaluating strategic alternatives for its commercialization[51]. - MIPLYFFA is being made available to NPC patients in multiple countries under a global Expanded Access Program (EAP)[45]. - The company is prioritizing the advancement of its clinical stage asset, celiprolol, while continuing to expand its pipeline through inorganic growth[37]. - Celiprolol is being developed for Vascular Ehlers-Danlos syndrome (VEDS) and is currently in a Phase 3 clinical trial, with 52 participants enrolled as of December 31, 2025[60]. - The DiSCOVER trial for celiprolol aims to enroll 150 VEDS patients, with 100 receiving celiprolol and 50 receiving placebo[60]. - Celiprolol, if approved, could significantly innovate the treatment of VEDS, currently lacking approved options in the U.S.[61]. - The company has established in-house capabilities for the launch of MIPLYFFA and OLPRUVA, including rare disease sales specialists and patient reimbursement services[88]. - AZSTARYS was commercially launched in the United States in July 2021, with commercialization rights sublicensed to Shanghai Ark Biopharmaceutical Co., Ltd. for Greater China[90]. Financial Performance - The company incurred a net loss of $105.5 million for the year ended December 31, 2024, but reported a net income of $83.2 million for the year ended December 31, 2025, primarily due to the sale of the PRV, resulting in net proceeds of $148.3 million[212]. - As of December 31, 2025, the company had an accumulated deficit of $422.1 million[212]. - For the year ended December 31, 2025, approximately 82% of the company's revenues were derived from commercial sales of MIPLYFFA® (arimoclomol)[208]. - The company has faced recurring negative net operating cash flows throughout its operating history and cannot predict when it may begin to generate positive cash flows consistently[212]. - The company holds about 87 active U.S. patents and 497 active foreign patents, with expiration dates ranging from 2029 to 2044[76]. Regulatory and Compliance - The FDA requires substantial resources for the approval process of pharmaceutical products, which is inherently uncertain[110]. - The Investigational New Drug application (IND) becomes effective 30 days after submission unless the FDA raises concerns[111]. - Clinical trials are conducted in three phases, with Phase 3 requiring one or two studies for NDA approval depending on disease severity[119]. - The FDA aims to complete its initial review of a standard New Drug Application (NDA) within 10 months and 6 months for priority NDAs[120]. - The FDA may require post-approval studies (Phase 4) to further assess the safety and effectiveness of approved products[126]. - Fast Track designation can expedite the review process for drugs intended to treat serious conditions and address unmet medical needs[127]. - Breakthrough Therapy Designation allows for expedited development for drugs showing substantial improvement over existing therapies[129]. - Orphan Drug Designation provides seven years of market exclusivity for drugs treating rare diseases affecting fewer than 200,000 individuals in the U.S.[130]. - The NDA review process may involve additional clinical data requests, and the FDA can issue a complete response letter detailing deficiencies[124]. - The FDA will inspect manufacturing facilities and clinical trial sites to ensure compliance with Good Manufacturing Practices (cGMP) and Good Clinical Practices (GCP)[122][123]. - The company must comply with stringent FDA regulations post-approval, including annual fees and compliance with cGMPs[135][136]. - Non-compliance with FDA regulations could lead to severe penalties, including withdrawal of marketing approval and significant fines[140]. - The company is subject to various healthcare regulations, including the Anti-Kickback Statute and False Claims Act, which impose strict compliance requirements[147][148]. Market Competition and Challenges - MIPLYFFA faces competition from AQNEURSA, which is approved for treating neurological manifestations of NPC, and other drug candidates in clinical development[93]. - OLPRUVA competes against marketed forms of phenylbutyrate, including RAVICTI and PHEBURANE, with authorized generics entering the market in Q4 2025[94]. - The company faces risks related to establishing effective sales, marketing, and distribution capabilities for its approved products, which may impact commercialization efforts[183]. - The company is subject to intense competition from various sources, including pharmaceutical and biotechnology companies, which may affect its market position[193]. - The company faces challenges in obtaining adequate reimbursement from third-party payors, which is critical for product adoption and revenue generation[186]. - The company operates in a complex international reimbursement landscape, with significant variations in pricing and reimbursement schemes across countries[191]. Intellectual Property - Intellectual property protection is critical for the company's technology and products, with risks associated with patent prosecution and potential litigation[229]. - The company faces uncertainties regarding patent applications, including the possibility of not obtaining meaningful protection or facing priority disputes[231]. - Legal proceedings related to intellectual property rights could significantly harm the company's business and financial condition[234]. Strategic Collaborations and Partnerships - The company plans to form strategic collaborations for commercialization of product candidates with large pharmaceutical organizations if they receive regulatory approval[91]. - A collaboration with Commave for the development and commercialization of AZSTARYS has been established, but its success is uncertain and may impact revenue generation[225]. - A dispute with Commave regarding the AZSTARYS License Agreement has arisen, with litigation ongoing that could affect the company's business and financial condition[226]. - The company may seek collaborations for product candidates, but competition and negotiation complexities could hinder timely agreements[227]. Operational Risks - The company relies on a limited number of suppliers, including sole-source suppliers, which increases the risk of supply disruptions[215]. - The company is dependent on a single specialty pharmacy in the United States and a single distributor in the EU for the distribution of MIPLYFFA, making its commercialization efforts vulnerable to the performance of these partners[221]. - The transition to new distributors, if necessary, could result in significant delays and negatively impact revenue[222]. - The company may need to increase expenditures for development or commercialization activities if collaborations are not established, potentially requiring additional capital[228].

Executive Compensation - The annual base salary for the Executive is set at $520,000, with payment made monthly[10]. - The Executive is entitled to a short-term incentive target of no less than 45% of the base salary, subject to performance goals[11]. - The Company will award the Executive 300,000 non-statutory stock options, vesting over four years[13]. - The Executive will participate in employee retirement and welfare benefit plans available to senior executives[14]. - The Company will reimburse the Executive for reasonable business expenses incurred during the employment[16]. - The Executive's principal place of employment will be in the Boston, MA, Metro Area[9]. Termination and Severance - The Executive's employment can be terminated by the Company with a 30-day notice[18]. - Upon termination without cause, the Executive will receive severance compensation equivalent to 12 months of base salary[24]. - The severance payments will include a pro-rated portion of any annual incentive compensation award[26]. - Severance compensation is subject to mandatory and voluntary payroll deductions, and will terminate if the Executive breaches post-employment covenants[30]. - Termination "with Cause" includes acts of malfeasance or misconduct resulting in material harm to the company[31]. - Termination "without Cause" does not relate to any acts constituting "Cause" and is not due to Executive's death or Total Disability[33]. - Total Disability is defined as being unable to perform essential job functions for 180 consecutive days[34]. - "Good Reason" termination requires a material change in authority, location, or salary without Executive's consent[35]. - Executive must provide notice of Good Reason within 60 days after the event, allowing the company 30 days to correct the issue[37]. - The company will pay the Executive 50% of their highest annualized base salary as "Garden Leave Payments" for a 12-month restriction period following termination[59]. Confidentiality and Intellectual Property - All intellectual property developed during employment is assigned to the company, and the Executive agrees to assist in protecting such rights[48]. - The term "Confidential Information" includes all business-related information developed during the Executive's employment, which is critical for maintaining the company's competitive advantage[52]. - The Executive acknowledges that the Confidential Information is a valuable asset for the company and its protection is essential[53]. - The Executive agrees not to disclose the terms of the Agreement, except to certain advisors, and any violation constitutes a material breach[104]. Non-Competition and Restrictive Covenants - The "Restricted Period" lasts throughout the Employment Term and continues for 12 months after termination initiated by the Executive[56]. - The Executive agrees not to engage in any competitive activities with the company for the duration of the Restricted Period[57]. - The company may seek injunctive relief and monetary damages in case of a breach of the Noncompetition Agreement[61]. Legal and Tax Provisions - The Agreement is governed by the laws of the State of Florida, with disputes to be litigated in Osceola County[76]. - The Executive is responsible for all applicable taxes on compensation and benefits under the Agreement[81]. - The Agreement includes provisions for the survival of certain terms, including restrictive covenants, after the termination of the Executive's employment[75]. - The agreement is intended to comply with Section 409A of the Code, which may delay payments for specified employees for six months after separation[70]. Indemnification and Cooperation - The Company will indemnify the Executive against any actions, suits, or claims arising from the Executive's performance of duties, covering costs and reasonable attorney's fees[72]. - The Executive agrees to cooperate with the Company in any litigation or investigation related to events during their employment, with reimbursement for reasonable expenses[82]. Acknowledgments and Waivers - Executive acknowledges that the payments and benefits provided in the Agreement are in consideration for the acceptance and execution of the Agreement[101]. - Company has satisfied all obligations owed to Executive under any employment agreement, and this Agreement supersedes prior agreements[102]. - The Executive has waived the right to recover monetary damages in connection with any claims under the Age Discrimination in Employment Act and other related laws[93]. - The Agreement may be revoked by Executive within seven days after execution, and it will not become effective until the expiration of this period[111].

Core Insights - Zevra Therapeutics reported a Q4 net revenue of $34.1 million, marking a 31% growth quarter-over-quarter, and a full-year net revenue of $106.5 million for FY 2025, primarily driven by MIPLYFFA's net revenue of $87.4 million [1][6] - The company achieved a net income of $83.2 million for FY 2025, translating to earnings per share (EPS) of $1.40 basic and $1.35 diluted, a significant turnaround from a net loss of $(105.5) million in FY 2024 [12][33] - MIPLYFFA, the company's therapy for Niemann-Pick disease type C, has shown strong performance and is positioned for further growth, with market access reaching 68% of covered lives in the U.S. [2][7] Financial Highlights - Q4 2025 net revenue included $26.4 million from MIPLYFFA, $0.4 million from OLPRUVA, $5.6 million in net reimbursements from the Expanded Access Program (EAP), and $1.8 million in royalties [12][10] - Operating expenses for Q4 2025 were $23.0 million, with R&D expenses at $2.6 million, a decrease from $8.4 million in Q4 2024, while SG&A expenses rose to $20.4 million [12][10] - The company had cash, cash equivalents, and securities totaling $238.9 million as of December 31, 2025, indicating strong financial flexibility [12][10] Product and Pipeline Developments - MIPLYFFA has been designated as an Orphan Medicinal Product by the European Medicines Agency (EMA), with a Marketing Authorisation Application currently under review [7][13] - The company enrolled eight patients in the Phase 3 DiSCOVER trial for Vascular Ehlers-Danlos Syndrome during Q4 2025, totaling 52 enrolled patients by year-end [4] - The EAP for MIPLYFFA has enrolled 113 patients globally, with a distribution agreement executed to broaden access beyond Europe [7][4] Strategic Focus - The company has relocated its global corporate headquarters to Boston to enhance access to specialized talent and is focused on executing multiple near-term growth opportunities in 2026 [2] - Zevra aims to create meaningful value for the rare disease community and its shareholders through disciplined execution of its strategic priorities [2][29]

Core Insights - Zevra Therapeutics, Inc. has appointed Justin Renz as Chief Financial Officer, effective March 9, 2026, bringing over 25 years of financial leadership experience in the biopharmaceutical industry [1][2] Company Overview - Zevra Therapeutics is a commercial-stage company focused on providing therapies for rare diseases, with its lead product targeting Niemann-Pick disease type C, a rare neurodegenerative disorder [4] - The company aims to broaden access through geographic expansion and has a pipeline of rare disease programs, emphasizing its patient-centric values of accountability, integrity, innovation, and courage [4] Leadership Background - Justin Renz has a strong track record in the biopharmaceutical sector, having previously served as Chief Financial & Operations Officer at Ardelyx, where he played a key role in launching two first-in-class medicines [2] - Renz also held leadership positions at Correvio Pharma, Karyopharm Pharmaceuticals, and Zalicus Inc., showcasing extensive experience in capital markets and strategic transactions [2][3]